Omeros’ (OMER) “Hold” Rating Reaffirmed at Needham & Company LLC

Share on StockTwits

Needham & Company LLC reaffirmed their hold rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Wednesday, AnalystRatings.com reports.

A number of other equities analysts also recently commented on OMER. BidaskClub downgraded Omeros from a sell rating to a strong sell rating in a report on Saturday, October 12th. HC Wainwright restated a buy rating and set a $35.00 target price on shares of Omeros in a report on Tuesday, November 5th. Maxim Group set a $32.00 target price on Omeros and gave the company a buy rating in a report on Friday, August 9th. Wedbush restated a hold rating and set a $18.00 target price on shares of Omeros in a report on Monday, October 28th. Finally, ValuEngine downgraded Omeros from a buy rating to a hold rating in a report on Wednesday, October 2nd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Omeros has a consensus rating of Hold and an average price target of $25.60.

OMER traded down $0.61 during midday trading on Wednesday, hitting $13.20. The stock had a trading volume of 525,200 shares, compared to its average volume of 478,581. The company has a market cap of $687.02 million, a P/E ratio of -5.95 and a beta of 2.78. The business has a fifty day moving average of $15.37 and a 200 day moving average of $16.90. Omeros has a 1 year low of $10.30 and a 1 year high of $20.92.

Omeros (NASDAQ:OMER) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.08. The business had revenue of $29.86 million for the quarter, compared to the consensus estimate of $27.19 million. Omeros’s revenue was up 547.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.81) EPS. On average, research analysts expect that Omeros will post -1.2 EPS for the current year.

In other Omeros news, Director Thomas J. Cable sold 5,000 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $15.12, for a total value of $75,600.00. Following the completion of the transaction, the director now owns 35,067 shares in the company, valued at $530,213.04. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 12.80% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of OMER. Nuveen Asset Management LLC bought a new position in Omeros in the second quarter worth $3,221,000. Chicago Equity Partners LLC bought a new position in Omeros in the second quarter worth $1,094,000. Ingalls & Snyder LLC raised its holdings in Omeros by 1.2% in the third quarter. Ingalls & Snyder LLC now owns 5,023,755 shares of the biopharmaceutical company’s stock worth $82,038,000 after purchasing an additional 58,198 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in shares of Omeros during the second quarter valued at $784,000. Finally, SG Americas Securities LLC increased its holdings in shares of Omeros by 61.0% during the third quarter. SG Americas Securities LLC now owns 130,823 shares of the biopharmaceutical company’s stock valued at $2,136,000 after acquiring an additional 49,548 shares in the last quarter. Institutional investors and hedge funds own 53.46% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: What is the formula for calculating total return?

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.